Clinical Trial Details


Research Study Summary

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive patients With Impaired Glucose Tolerance or Impaired Fasting Glucose


Blood Pressure and Metabolic Effects of Nebivolol Compared with Hydrochlorothiazide and Placebo in Hypertensive patients with Impaired Glucose Tolerance or Impaired Fasting Glucose.

Inclusion Criteria:

  • Male or female, ambulatory outpatients 18-80 years old at screening.
  • Have a history of hypertension
  • Qualifying laboratory results

Exclusion Criteria:

  • Severe Hypertension, including chronic renal disease
  • Use of niacin or anti-diabetic medication (oral or injectable) within 6 months of study
  • Have clinically significant respiratory, liver, or cardiovascular disease
  • Presence of coronary artery disease requiring treatment with a beta blocker, calcium channel blocker or nitrates
  • Have a history of hypersensitivity to nebivolol, other beta-blockers, or other sulfonomide-derived drugs.

To Learn more

CW ID: 157673
Date Last Changed: July 24, 2013

Clinical Trial Snapshot

Both Male and Female
18 to 80 Years
Overall Status
Facility Type


Diablo Clinical Research
1365 Corte Loma
Walnut Creek, CA 94598
Phone: 925-930-7267
Fax: 925-930-7392

View Map

Research Center Information:

Diablo Clinical Research

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.